DGAP-News: Press Release: 4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases
(firmenpresse) - DGAP-News: 4SC AG / Key word(s): Agreement/Alliance
Press Release: 4SC Discovery and LEO Pharma announce exclusive
research and license agreement for inflammatory skin diseases
26.02.2013 / 07:30
---------------------------------------------------------------------
Press Release
4SC Discovery and LEO Pharma announce exclusive research and license
agreement for inflammatory skin diseases
Planegg-Martinsried, Germany and Ballerup, Denmark, 26 February 2013 - 4SC
AG (Frankfurt, Prime Standard: VSC), a discovery and development company of
targeted small molecule drugs for autoimmune diseases and cancer, today
announced that its fully-owned research subsidiary 4SC Discovery GmbH has
entered into an exclusive research and license agreement with
pharmaceutical company LEO Pharma A/S, Ballerup, Denmark with the primary
aim of jointly researching, developing and commercialising an oral
treatment for inflammatory skin diseases such as psoriasis.
The collaboration has the potential to result in a novel and convenient
breakthrough therapy for chronic skin conditions. The innovative compound,
currently in the early development state, has already been proven in
preclinical models to significantly reduce if not entirely eradicate
symptoms of psoriasis.
Under the agreement, LEO Pharma will issue an upfront payment of EUR 1
million to 4SC Discovery and additional funding for research and
development. LEO Pharma will receive an exclusive option to license the
worldwide marketing and commercialisation rights of the compound for use in
inflammatory skin diseases, including psoriasis and other therapeutic
areas. Upon LEO Pharma exercising the option, 4SC Discovery will be
eligible for a milestone payment of up to EUR 3 million and further
payments upon achieving specific development milestones of up to EUR 92
million as well as up to double-digit royalties.
Improving quality of life
The deal marks the latest milestone in LEO Pharma's ambitious growth
strategy, which involves actively seeking new opportunities to expand the
company pipeline for the benefit of patients.
Kim Kjøller, Senior Vice President, Global Development, LEO Pharma, said:
'LEO Pharma is excited about the agreement with 4SC and the possibilities
it offers patients. The compound has the potential to completely eradicate
symptoms of psoriasis, liberating people from the burden of this chronic
skin disease. LEO Pharma strives to constantly expand and improve treatment
options for patients and this latest deal is the perfect example of our
commitment to meeting patient needs with breakthrough novel therapies.'
New breakthrough therapy
For 4SC Discovery, the deal marks a key early-stage partnering deal with
one of the company's compounds from its research.
Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief
Scientific Officer at 4SC AG, comments: 'We are delighted to have won LEO
Pharma, a global leader in skin diseases, as an ideal research and license
partner for our highly innovative compound, which is based on the
modulation of cytokines. Our goal is now to speed up and jointly develop a
novel breakthrough therapy addressing the high medical need in chronic
inflammatory skin diseases such as psoriasis. This partnership again
demonstrates the great expertise and scientific potential of 4SC in the
fields of autoimmune and inflammatory diseases.'
Dr. Ulrich Dauer, Chief Executive Officer of 4SC AG, adds: 'We are proud
that our research subsidiary 4SC Discovery GmbH has entered into an
early-stage partnering deal with such a renowned partner as LEO Pharma.
This licensing partnership is another strong signal for the value
generation potential of 4SC's research and another clear fulfilment of the
promise we made to the capital markets a year ago when we started 4SC
Discovery with the intention to focus on a stronger commercialisation of
our early-stage research activities.'
Ends
About Leo Pharma A/S
Founded in 1908, LEO Pharma is an independent, research-based
pharmaceutical company. LEO Pharma develops, manufactures and markets
pharmaceutical drugs to dermatologic and thrombotic patients in more than
100 countries globally. To realise our vision of becoming the preferred
dermatology care partner improving people's lives around the world, we are
expanding into new regions and markets, reaching more patients and
societies with drugs and therapies that address unmet medical needs. LEO
Pharma has its own sales forces in 61 countries and employs around 5,000
employees worldwide. The company is headquartered in Denmark and is wholly
owned by the LEO Foundation.
About 4SC Discovery GmbH and 4SC Group
4SC Discovery GmbH, a wholly-owned subsidiary of 4SC AG, specialises in the
early-stage research and discovery of novel therapeutic compounds against
cancer and autoimmune diseases. 4SC Discovery offers its technologies and
research services to other companies and engages in partnerships with
pharmaceutical and biotech companies to accelerate the development and
commercialisation of its own early-stage therapeutic programmes. 4SC Group
focuses on the discovery and clinical development of targeted
small-molecule drugs for the treatment of cancer and autoimmune diseases in
order to enhance patients' quality of life. At the end of 2012, 4SC Group
had 86 employees. The company was founded in 1997 and has been listed on
the Prime Standard of the Frankfurt Stock Exchange since December 2005.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
For more information on 4SC or 4SC Discovery please visit www.4sc.com and
www.4sc-discovery.de or contact:
4SC AG
Jochen Orlowski, Corporate Communications&Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-63-66
MC Services
Raimund Gabriel, Mareike Mohr
raimund.gabriel(at)mc-services.eu, Tel.: +49-89-2102-2830
mareike.mohr(at)mc-services.eu, Tel.: +49-89-2102-2840
The Trout Group
Chad Rubin
Crubin(at)troutgroup.com, Tel.: +1-646-378-2947
For more information about LEO Pharma please visit www.leo-pharma.com or
contact:
LEO Pharma A/S
Eva Juul Langlands, Corporate Communications Manager
eva.langlands(at)leo-pharma.com, Tel.: +45-4188-3094
End of Corporate News
---------------------------------------------------------------------
26.02.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: +49 (0)89 7007 63-0Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
202215 26.02.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.02.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 233132
Anzahl Zeichen: 10393
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 293 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Press Release: 4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
